WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024 with the reorganizations of its food center and the office that inspects FDA-regulated facilities.
Amid that massive reorganization, the FDA also will lose one of its most influential leaders. Janet Woodcock is retiring at the beginning of the year after decades of service. She helped guide some of the most impactful changes to the regulation of medicine and was a steady hand on the agency’s tiller throughout several administrations.
The agency also will likely need to decide whether to take action on the regulation of lab-developed diagnostics, and it’s getting serious about making clinical trials more representative of the people that drugs treat.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect